This article explains, in educational terms, microwave ablation — how the technology works and where it fits. Beyond needle-based approaches, focused laser energy delivered through endoscopic instruments can be used trans-urethrally to vaporize or coagulate bladder tumors and to treat benign prostatic hyperplasia (BPH) with the aim of limiting bleeding. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Percutaneous Tumor Ablation
RFA has an extensive track record in hepatocellular carcinoma (HCC), MWA is frequently applied to liver and lung tumors, and cryoablation is often described for renal cell carcinoma, though indications are always defined by the treating team. Beyond needle-based approaches, focused laser energy delivered through endoscopic instruments can be used trans-urethrally to vaporize or coagulate bladder tumors and to treat benign prostatic hyperplasia (BPH) with the aim of limiting bleeding. Percutaneous tumor ablation is a group of minimally invasive techniques in which energy is delivered through a needle-like applicator, placed through the skin under imaging guidance, to destroy a focal tumor in situ.
Microwave Ablation (MWA) Systems
Microwave ablation generates an oscillating electromagnetic field at the antenna tip that agitates water molecules, producing frictional heat that can create a cytotoxic ablation zone in seconds to minutes. Compared with radiofrequency energy, microwave energy is often described in the literature as less susceptible to tissue charring and to the heat-sink effect near larger vessels, which may support more uniform heating. Antenna gauge, active-tip length, and generator power (measured in watts) are the primary variables a clinician balances against the intended ablation zone size for a given lesion. MWA is frequently discussed for liver and lung tumors, but suitability, applicator selection, and power protocol are determined case by case by the interventional physician.
Design and Technical Notes
INVAMED groups its ablation portfolio by the energy modality and anatomical target, offering radiofrequency platforms for soft tissue and bone as well as an intracavitary hypothermia set. Each device is intended for use by trained clinicians under appropriate image guidance and per the instructions for use (IFU). Image guidance with ultrasound, CT, or other modalities supports accurate applicator placement and monitoring of the treatment zone. For lesions near large vessels, the heat-sink effect can influence the completeness of heat-based ablation and is factored into planning.
Key Considerations
- Manufacturer descriptions of INVAMED platforms reflect intended design and applications rather than guaranteed individual outcomes.
- All INVAMED ablation devices are intended for use by trained clinicians under appropriate image guidance and in accordance with the IFU.
- For lesions near large vessels, the heat-sink effect can influence the completeness of heat-based ablation and is factored into planning.
Frequently Asked Questions
Is the HyperTiss set an ablation device?
INVAMED describes HyperTiss as an intracavitary (intravesical) temperature-therapy set intended for adjunctive use with intravesical chemotherapy in bladder cancer, rather than as a standalone tumor ablation device.
What determines the ablation zone size?
Published sources note that factors such as generator power, applicator design, application time, and local blood flow influence the ablation zone, and settings are selected by the treating physician.
Does ablation replace surgery?
Not necessarily; ablation is a local, minimally invasive option that may be considered instead of or alongside surgery in appropriately selected patients, and the decision is made within a multidisciplinary team.
About INVAMED
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Clinical and Technical Context
Intracavitary hypothermia describes controlled temperature therapy delivered directly into a body cavity such as the bladder, and is generally positioned as an adjunct intended to enhance the penetration of intravesical chemotherapy. This is an endoscopic energy technique whose indication and parameters are established by the treating urologist rather than by any general rule. Percutaneous tumor ablation is a group of minimally invasive techniques in which energy is delivered through a needle-like applicator, placed through the skin under imaging guidance, to destroy a focal tumor in situ. INVAMED's generator-based platforms, including the Peta RFA System and ThermoEdge RFA Platform, are built to drive such applicators across several soft-tissue applications.
Related on INVAMED
- Oncology Ablation — product category
- Fusion Intraosseous Radiofrequency Ablation System for Spinal Tumors — Technical Overview
- Microwave ablation (MWA) vs Radiofrequency ablation (RFA): What Is the Difference?
- Peta Radiofrequency Ablation (RFA) System — Technical Overview
Important Disclaimer
This content is educational and technical in nature and must not be interpreted as medical advice or as a promise of any clinical outcome. Individual results depend on many factors and can only be evaluated by a treating physician. Figures attributed to INVAMED reflect manufacturer or published data and are not a guarantee of results. All INVAMED devices are to be used by trained clinicians per the approved IFU, and availability is subject to local regulatory status.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.